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Purpose: Koetjapic acid is an active compound of a traditional medicinal plant, Sandoricum koetjape. Although
koetjapic acid has a promising anticancer potential, yet it is highly insoluble in aqueous solutions. To increase
aqueous solubility of koetjapic acid, we have previously reported a chemical modification of koetjapic acid to
potassium koetjapate (KKA). However, pharmacokinetics of KKA has not been studied. In this study, pharma-
cokinetics and antiangiogenic efficacy of KKA are investigated.
Methods: Pharmacokinetics of KKA was studied after intravenous and oral administration in SD rats using HPLC.
Anti-angiogenic efficacy of KKA was investigated in rat aorta, human endothelial cells (EA.hy926) and nude
mice implanted with matrigel.
Results: Pharmacokinetic study revealed that KKA was readily absorbed into blood and stayed for a long time in
the body with Tmax 2.89 ± 0.12 h, Cmax 7.24 ± 0.36 μg/mL and T1/2 1.46 ± 0.03 h. The pharmacological
results showed that KKA significantly suppressed sprouting of microvessels in rat aorta with IC50 18.4 ± 4.2 μM
and demonstrated remarkable inhibition of major endothelial functions such as migration, differentiation and
VEGF expression in endothelial cells. Further, KKA significantly inhibited vascularization in matrigel plugs
implanted in nude mice.
Conclusions: The results indicate that bioabsorption of KKA from oral route was considerably efficient with
longer retention in body than compared to that of the intravenous route. Further, improved antiangiogenic
activity of KKA was recorded which could probably be due to its increased solubility and bioavailability. The
results revealed that KKA inhibits angiogenesis by suppressing endothelial functions and expression of VEGF.
1. Introduction
It is a well-known fact that poor solubility and dissolution in the
gastrointestinal fluids are limiting factors for many drugs which pose a
critical problem in bioavailability upon oral administration. Solubility
is one of the vital factors to achieve desired concentration of drug in
systemic circulation and to produce an effective pharmacological re-
sponse. Low aqueous solubility is a major hurdle which is usually en-
countered during development of pharmaceutical formulations. In
order for a drug to be absorbed, it has to be converted into a solution
form at the site of absorption. Therefore, solubility has become the
biggest challenge for pharmaceutical researchers working in the drug
delivery system.
Sandoricum koetjape Merr. (Meliaceae) is a traditional medicinal
plant and native to Malaysia, Cambodia and Southern Laos. Previously,
we have reported that koetjapic acid (KA) is the active principle of S.
koetjape which contributes towards the anticancer activity of this herb
against human colon cancer cell line [1]. However, it was observed that
KA has poor solubility in water as well as in other cell culture permitted
solvents i.e., dimethyl sulfoxide, thus posing an obstacle to further re-
search and its clinical application. In order to enhance solubility of KA,
we have reported a chemical modification of KA into its salt form,
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potassium koetjapate [2]. Potassium koetjapate (KKA) showed en-
hanced aqueous solubility and thereby it exhibited in vitro efficacy.
In the present study bioavailability of potassium koetjapate (KKA)
was investigated in Sprague Dawley Rats using HPLC. In addition, KKA
was tested for its antiangiogenic activity using a series of ex vivo and in
vitro angiogenesis based experimental models such as rat aortic ring
assay, and the proliferation, differentiation and migration properties of
human endothelial cells.
2. Material and methods
2.1. Animals
Male Sprague Dawley rats weighing 350−410 g were obtained from
the Animal Research and Service Centre (ARASC), Universiti Sains
Malaysia, Penang, Malaysia. The animals were maintained in a 12 h
light-dark cycle, at room temperature and were allowed free access to
standard food pellets. Animal ethics Reference number: USM/IACUC/
2018/(111)(913).
2.2. Preparation of different concentrations of potassium koetjapate (KKA)
A stock solution of KKA was prepared by dissolving 10mg of KKA in
1mL distilled water to obtain 10mg/mL concentration. For cell in vitro
studies, further dilutions were prepared using culture media following
the serial dilution method.
2.3. Evaluation of bioavailability of potassium koetjapate (KKA)
The study was conducted according to a two-way crossover study
design. Healthy and adult SD rats were fasted overnight with free access
to water prior to the experimentation. Food was only allowed 4 h after
the sampling of blood. In the first occasion, 3 rats (group I) were ran-
domized to receive 50mg/kg of KKA (dissolved in water) administered
intravenously via the tail vein, while three other rats (group II) received
orally 50mg/kg of the same sample. After a washout period of 2 weeks,
the animals from group (I) were given 50mg/kg of KKA orally, whilst
those from group (II) received 50mg/kg intravenously of KKA. The rats
were placed in animal restraining cages during blood collection and
blood samples of 0.25–3mL were withdrawn from the tail vein at 0, 5,
15, 30, 60, 90,120, 150, 180, 240, 300, 720, and 1440min after in-
travenous injection or oral administration of the test sample. The blood
samples were collected into microcentrifuge tubes containing 20 μL of
heparin solution. All blood samples were centrifuged at 3000 rpm for
10min. The resulting plasma samples were kept at −20 °C prior to
HPLC analysis. An aliquot of 200 μL plasma was added in a 1.5 mL
micro-centrifuge tube, and mixed with 200 μL HPLC grade methanol
containing 10 μg/mL of betulinic acid (BA) as an internal standard. The
mixture was vortexed for 2min followed by centrifugation at 8000 rpm
for 10min. The supernatant was transferred into a 0.15mL glass conical
insert. For analysis, 20 μL of supernatant was injected into the HPLC
system. Chromatographic condition for HPLC analysis of KA and BA
was set according to the method described previously [3]. The chro-
matographic analysis was carried out on a ZORBAX Eclipse Plus C8
column (250×4.6mm internal diameter ×5 μm particles size) (Agi-
lent, USA) at 30 °C and the injection sample (10 μL) was eluted with an
isocratic mobile phase comprising of acetonitrile-water (9:1) pH 2.5
(with trifluoroacetic acid). Flow rate was adjusted to 1mL/min and
detection was carried out at 210 nm wavelength.
2.3.1. Assay validation
KKA calibration curve was constructed by spiking KKA-free pooled
rat plasma (200 μL) with a known amount of KKA at a concentration
range of 0.3125−10 μg/mL. Followed by the addition of 200 μL me-
thanol containing 10 μg/mL BA for extraction of KKA from spiked
pooled plasma. These plasma standards were also used for the
determination of Lower Limit of Detection (LLOD) and Lower Limit of
Quantification (LLOQ), the extraction recovery, intra-day and inter-day
precision and accuracy (n=6) of the method [4].
2.3.2. Determination of pharmacokinetic parameters
The pharmacokinetic parameters estimated from the data of IV
administration were, area under plasma concentration-time curve
(AUC0→∞), elimination rate constant (Ke), biological half-life (t1/2),
volume of distribution (Vd), and clearance (CL). The value of AUC0→∞
(μg h/mL) was determined by adding the area from time zero to the last
sampling time (AUC0→t) and to the area from last sampling time to
infinity (AUCt→∞). The Ke (h−1) was calculated using the relationship,
t1/2=ln 2/Ke while Vd (L/kg) was calculated from the relationship,
Vd= dose/Ke×AUC0→∞. Clearance CL (L/kg h) was calculated from
the relationship, CL= dose/AUC0→∞. Whereas from the data of oral
administration, area under plasma concentration-time curve AUC0→24
(μg h/mL), maximum concentration (Cmax) and time to reach Tmax to
maximum concentration were calculated. The percentage of absolute
bioavailability of the standard compounds was estimated from the
following equation [5]:
Fig. 1. HPLC Method Development.
A) HPLC chromatogram of blank rat plasma.
B) HPLC chromatogram of rat plasma spiked with betulinic acid (BA) and po-
tassium koetjapate (KKA) at retention times (Rt) values 8.3 and 11.7min, re-
spectively.
Standard calibration curve of potassium koetjapate (KKA) in rat plasma de-
picting the linear regression curve.
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%Absolute bioavailability (F) = (AUC for oral/AUC for IV) × (IV dose/
oral dose) × 100
The samples were analyzed in triplicates and results were presented
as mean ± SEM, n= 6.
2.4. Anti-angiogenic studies
2.4.1. Culture conditions and maintenance of cell lines
Human umbilical vein (EA.hy926, ATCC® CRL-2922) cell lines were
purchased from the American Type Culture Collection (Rockville, MD)
and were cultured and maintained in Roswell Park Memorial Institute-
1640 (RPMI-1640). Media was appended with 5–10 % heat inactivated
fetal bovine serum (Kansas, USA) and 1% penicillin/streptomycin [2].
Additionally, EA.hy926 cells were propagated in endothelial cell
medium supplemented with 1 % endothelial cell growth supplements
(ECGS). All cell lines were cultured in a humidified incubator at 37 °C
supplied by 5 % CO2, and were monitored frequently to detect the
presence of any contamination such as bacterial or fungal growth.
Hemocytometer was used to count the cells as described by the earlier
method [6].
2.4.2. Assessment of proliferation of endothelial cells
MTT assay was used to study the effect of KKA on proliferation of
human endothelial cells (EA.hy926) [7]. The assay plates were read
using a microtiter plate reader (Multiskan Ascent microplate reader,
Thermolab system 354, Finland) at 570 nm absorbance. Culture media
alone was used as a negative control. KA alone was also used as a re-
ference for comparison.
2.4.3. Cell migration assay
The assay was carried out as described previously [8]. Briefly,
EA.hy926 cells were plated in 6 well plates until a confluent monolayer
was formed after which a wound was created with 200 μL micropipette
tips. The detached cells were removed by washing them twice with PBS
(MediaTech, USA) and the plates were treated with KKA. The wounds
were photographed after 12 and 18 h. The width of the cell-free wound
was measured under an inverted light microscope supplied with Leica
Quin computerized imaging system. Ten fields per well were photo-
graphed and a minimum of 30 readings per field were measured.
The percentage of wound closure was then calculated relative to
zero time using the formula: % wound closure= 1−(the width at the
indicated times (h) /the width at zero time 100 %:
The results were presented as average ± SD, (n= 3).
2.4.4. Tube formation assay
The ability of EA.hy926 to form tube-like structures was in-
vestigated on Matrigel matrix (BD Bioscience, USA) [9]. Briefly, the
matrigel matrix was allowed to polymerise for 45min at 37 °C and 5%
CO2. Then EA.hy926 were trypsinized and seeded (3×104 cells per
Table 1
Calibration data, LOD and LOQ of the reported HPLC method.
Compound LOD (μg/mL) LOQ (μg/mL) Linearity range (μg/mL) Equation R2 Value
KA 0.10 0.31 0.3125−10 y= 0.5298x + 0.1972 0.999
Table 2
Plasma extraction recovery of koetjapic acid (KA).
Name Concentration Recovery
(μg/mL) Mean RSD (%)
KA 0.3125 96.41 0.87
0.625 96.58 1.34
1.25 97.97 1.56
2.5 99.34 2.10
5 95.60 1.64
10 98.82 1.39
Table 3
Intra-day and inter-day precision (n= 6).
Compounds Concentration Within Day Between day
(μg/mL) Accuracy
(% of true
value)
RSD (%) Accuracy
(% of true
value)
RSD (%)
KA 0.3125 102.70 0.45 100.36 1.65
0.625 96.79 1.87 97.75 1.31
1.25 92.33 1.07 91.69 1.59
2.5 96.45 1.79 95.06 1.08
5 97.95 0.89 97.42 0.96
10 101.98 2.00 101.35 1.80
Fig. 2. HPLC profile obtained in pharmacokinetic study.
A) Chromatogram of KKA (50mg/kg body weight) in rat plasma at 2 h after oral administration.
B) Chromatogram of KKA (50mg/kg body weight) in rat plasma at 2 h after intravenous administration.
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well) in 100 μL of RPMI-1640 (GE Healthcare HyClone, USA) culture
medium with triplicates of different concentrations of KKA. After 6 h,
the tube-like structures were visualized and imaged under light mi-
croscopy at 4× magnification. The area occupied by the capillary-like
structures was then measured on treatment and control groups by
Image J software and the results were shown as a quantified of width
and length of tube-like structure of treated and untreated cells The
results were demonstrated as a average ± SD, (n=3).
2.5. Ex vivo rat aortic ring assay
Rat Aortic Ring Assay was conducted with the following method
[10]. In short, aortic rings with 1mm width taken from thoracic aortas
of 12–14 weeks old male Sprague Dawley rats were seeded separately in
a 48-well plate in 300 μL serum free M199 media mixed with 3mg/mL
fibrinogen and 5mg/mL aprotinin. 50 NIH U ml−1thrombin in 0.15M
NaCl were pipetted in each well. Afterwards incubated for 90min at
37 °C, followed by adding 6 different concentrations of KKA dissolved in
0.3 mL M 199 medium containing 20 % HIFBS, 0.1 % έ-aminocaproic
acid, 1% L-Glutamine, 2.5 μg/mL amphotericin B, and 60 μg/mL gen-
tamicin (Sigma, Germany), to each well while botulinic acid and DS
water were used as positive and negative controls, respectively. The
medium was changed with a fresh one mixed with the compound on the
fourth day. On the next day, aortic rings were imaged using an inverted
light microscope at 4× magnification. Then, the length of blood vessels
outgrowth from the primary tissue explants was measured using the
Leica Quin software package following the methods described by Ni-
cosia [7,11]. The results were illustrated as mean percent inhibition to
the negative control ± SD, (n=3). The inhibition of blood vessels
formation was calculated according to the following formula:
Blood vessels inhibition = (1- (A0/A)) * 100
In which, A0 = distance of blood vessels growth in treated rings
with KKA in μm, A=distance of blood vessels growth in the control in
μm.
2.6. Assessment of VEGF levels in endothelial cells
The effect of KKA on the release of angiogenic cytokine (VEGF) from
endothelial cells was determined using a human VEGF-165 ELISA kit
(Raybio, USA) as per the manufacturer’s guidelines. In short, 60–70 %
confluent cultures of EA.hy926 were treated with 75 and 150 μM of
KKA and 75 μM and 150 μM of KA. Then, cell lysates were prepared
using the supplied cell lysis buffer. This assay employs an antibody
specific for human VEGF coated on a 96-well plate. Standards and
EA.hy926 lysates were pipetted into the plate. VEGF present in the
samples bounded with the immobilized antibody. The wells were wa-
shed and a biotinylated anti-human VEGF antibody was added before
the wells were washed again. Subsequently, HRP-conjugated strepta-
vidin was added to the wells. After washing, the coloring agent
Tetramethylbenzidine substrate solution was pipetted to the wells. The
Stop Solution (H2SO4) was added to each well, and the intensity of the
color was measured at 450 nm. At the time of experiment a calibration
curve of VEGF standard was prepared. The concentration of VEGF in
cell lysates was calculated using the log-log regression equation of the
best fit line of the standard calibration curve; (y= 0.0099×0.6137,
R2= 0.996).
2.7. In vivo matrigel plug assay
In vivo antiangiogenic activity of KKA was studied using the matrigel
sponge model of angiogenesis followed by the protocol [12]. In brief,
NU/Nu immunocompromised nude mice were injected subcutaneously
with 0.3mL of Matrigel appended with 100 μL of HCT-116 cells,
(1× 106 / ml RPMI-1640), close to the abdominal midline. Next, the
mice were treated orally in three different doses: 50, 100, and 200mg/
kg of KKA daily for two weeks. Distilled water and imatinib (100mg/
kg) were used as the negative and positive controls, respectively. In the
last day of the experiment, the animals were euthanized and Matrigel
plugs were excised. The Matrigel plugs were fixed in paraffin and cut.
Then, paraffin block sections (5 μm at thickness) were stained with
hematoxylin and eosin (H&E). Subsequently, the number of blood
vessels in all sections was measured. Ten microscopic fields per slide
were studied at 20× and 40× magnification and photomicrographic
images were taken by a digital camera. Then, the numbers of blood
vessels were compared between the treatment and control groups [13].
Fig. 3. The pharmacokinetic profiles of KKA
(50mg/kg) in rats.
A) Mean plasma concentration of KKA vs. time
profile after intravenous administration at in
rat plasma (data presented as mean ± S.E.M,
n= 6).
B) Mean plasma concentration of KKA vs. time
profile after oral administration at in rat
plasma (data presented as mean ± S.E.M,
n= 6).
Table 4
Pharmacokinetic parameters of koetjapic acid (KA) in rat plasma after in-
travenous administration (n=6).
Data Unit KA
AUC(24-∞) μg h/mL 84.87 ± 4.71
Ke h−1 1.30 ± 0.04
t1/2 h 0.54 ± 0.02
Vd L/kg h 0.15 ± 0.01
CL L/kg h 0.20 ± 0.01
Table 5
Pharmacokinetic parameters of koetjapic acid (KA) in rat plasma after oral
administration) (n= 6).
Data Unit koetjapic acid
C max μg/mL 7.24 ± 0.36
T max h 2.67 ± 0.12
Oral bioavailability % 32.14 ± 3.06
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3. Results and discussion
3.1. Method validation
KKA was well-separated from potential interfering compounds in rat
plasma under the described chromatographic conditions.
Chromatographic peak was identified with the aid of a pure standard of
KKA based on retention time. The chromatogram of blank rat plasma
and plasma spiked with BA (as an internal standard) and KKA are
shown in Fig. 1A and B, respectively. The retention times (Rt) for BA
and KKA were recorded at 8.3 and 11.7min, respectively.
The linearity of detector response was assessed for extracted plasma
samples. Linearity was evaluated by determining a series of six con-
centrations of the KKA standard solution in three replicates. A linear
regression equation and correlation coefficient were established from
the graph by plotting the plotting concentration versus corrected re-
sponse (peak area of KKA to the peak area of BA). The standard cali-
bration curve developed for KKA in rat plasma is given in the Fig. 1C.
The results showed that the curve obtained for KKA in plasma was
linear in the concentration range of 0.3125−10 μg/mL (y= 0.5298x +
0.1972, R2=0.999). The LLOD and LLOQ were 0.10 and 0.31 μg/mL,
respectively (Table 1).
Deproteinization with methanol gave a high percentage recovery
ranging from 95.60 % to 99.34 %, with %RSD 0.87–2.10 indicating a
good accuracy of the method (Table 2). Thus, implying that deprotei-
nization of the plasma with methanol did not result in any substantial
loss of the chemical constituents. The peak area ratio of KKA over the
internal standard (BA) peak area was used to calculate the %RSD of
KKA. Intra-day and inter-day precisions were estimated for the 6 re-
plicates of standard KKA samples at six different concentrations in
plasma. Intra-day and inter-day precision data are presented in Table 3.
The results revealed that, quite acceptable precision values in the range
of 91.69–102.70% were obtained with the method as the mean %RSD
for KKA was<2 %. These results indicate that the method is reliable,
repeatable and reproducible. Overall, the above results demonstrated a
rapid, simple and sensitive HPLC analytical method for KKA analysis in
Fig. 4. Anti-proliferative effect of KKA on
EA.hy926 cells.
A) Photomicrographic image of untreated
(negative control) EA.hy926 cells shows con-
fluent monolayer.
B) Photomicrographic image of the cells
treated with Betulinic Acid (50 μM) demon-
strates significant cytotoxic effect with reduced
doubling population.
C) Photomicrographic image of the cells
treated with koetjapic acid (50 μM) demon-
strated strong cytotoxicity against the en-
dothelial cells.
D) Photomicrographic image of the cells
treated with KKA (50 μM) demonstrated poor
cytotoxic effect as the cellular population was
not significantly affect when compared to that
of the negative control.
E) Graphical representation of dose-dependent
effect of KKA and KA on viability of EA.hy926
cell. Values are expressed in mean ± SD of
three independent experiments (n= 3).
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rat plasma samples.
3.2. Bioavailability of KKA in rats
Following single dose (50mg/kg body weight) administration of
KKA in the rats, no adverse reactions were observed in both groups
(intravenous and oral) of rats. The validated HPLC method was em-
ployed to study the pharmacokinetic behaviors of KKA in rat plasma
after IV and oral administration of KKA. As shown in Fig. 2, KKA was
well-separated from interference components in plasma by the devel-
oped HPLC method after oral (Fig. 2A) and intravenous (Fig. 2B) ad-
ministrations.
The curves of mean plasma concentration versus time profiles of
KKA after intravenous and oral administration of KKA are depicted in
Fig. 3A and B, respectively. Results were derived from the mean of
calculated concentration from three replicate injections. The in-
travenous and oral pharmacokinetic parameters of KKA were calculated
and presented in Tables 4 & 5 . Percentage of the oral bioavailability
was calculated by using AUCoral/dose divided by AUCiv/dose.
After 50mg/kg intravenous injection, the concentration of KKA
reached a maximum of 10.8 ± 2.3 μg/mL, and t1/2 was 0.54 ± 0.02 h.
However, after the oral administration of KKA (50mg/kg) was ab-
sorbed slowly and reached Cmax 7.24 ± 0.36 μg/mL at 2.89 ± 0.12 h,
and t1/2 was 1.46 ± 0.03 h. Furthermore, following intravenous ad-
ministration, KKA showed a gradual decline in its plasma concentra-
tions (Fig. 3A). The estimated distribution volume (Vd) of KKA was
0.15 ± 0.01 L/kg h. This suggests that KKA was less distributed into
the tissue compartment (Table 4). However, KKA appeared to be clear
from the body slowly with its small mean clearance value 0.20 ± 0.01.
In addition, KKA showed a small half-life (0.54 ± 0.02). Therefore, it
could be suggested that KKA was less distributed into the tissue and
retained in the blood compartment for a shorter time. After oral ad-
ministration, an increase of the plasma concentration of KKA was ob-
served in the plasma samples (Fig. 3B). This may indicate a gradually
Fig. 5. Effect of KKA on sprouting of micro-
vessels in rat aortic explants. The aortic rings
were photographed at 4× magnification, after
five days of treatment.
A) Rat aortic ring treated with 0.1 % DMSO
(negative control) shows formation of promi-
nent microvessels.
B) Rat aortic ring treated with 12.5 μM KKA.
C) Rat aortic ring treated with 25 μM KKA.
D) Rat aortic ring treated with 50 μM KKA.
E) Rat aortic ring treated with 100 μM KKA.
F) Rat aortic ring treated with 24 μM betulinic
acid.
G) Graphical representation of dose-dependent
inhibitory effect on spouting of microvessels in
rat arotic explant. Values shown are
mean ± SD of three independent experiments
(n=3). * = p < 0.05, ** = p < 0.01 and
*** = p < 0.001. NC=negative control;
PC= positive control.
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increased absorption of KKA into the blood. The results also indicate
that KKA stayed in the body for a relatively long time, as the Cmax
7.24 ± 0.36 μg/mL in 2.89 ± 0.12 h. The AUC0 values of KKA for the
intravenous group and the oral group was 83.87 ± 4.71 and
26.92 ± 0.01 μg L/mL, respectively. A significantly high AUC0 value of
KKA was obtained in the oral group which indicates a great absorption
and utility of this compound in rat plasma. These results indicated that,
after oral administration, KKA was absorbed and eliminated slowly.
Further, the results imply that after oral administration, KKA was re-
tained in the body for a longer period than that of the intravenous
administration. The mean residence time (MRT) for the intravenous
group and the oral group were 1.43 ± 0.11 and 2.51 ± 0.42 h, re-
spectively. Thus, the absolute bioavailability of KKA by oral route was
32.09 ± 3.06 %, and this reveals that the KKA is readily bioavailable
via oral route.
It is reported that more than 50 % of oral therapeutic agents were
used in the form of salts [14]. A study showed that salt formation is the
most common and effective method for acidic and basic drugs to en-
hance solubility, rate of bioabsorption and bioefficacy of such drugs
[15]. This fact indicates that the salification (salt formation) of a drug
molecule is a crucial procedure in development of a drug formulation.
The chief objective of the current study was to investigate the bioa-
vailability and bioefficacy of potassium koetjapate. Pharmacokinetic
results demonstrated that KKA was readily bioavailable and stayed in
the body for a relatively long time after oral administration. It is re-
ported that most of the triterpenoids show poor absorption and limited
oral bioavailability [16,17]. However, the present study exhibited that
salification of the triterpenoid, koetjapic acid, enhances its bioavail-
ability.
3.3. Anti-angiogenic effect of KKA
3.3.1. KKA inhibits the proliferation of endothelial cells
The effect of different concentrations of KKA and KA on the viability
of EA.hy926 cells were illustrated in Fig. 4. The photomicrographic
images of untreated EA.hy926 cells (negative control) show full con-
fluent monolayer (Fig. 4A), whereas the positive control, betulinic acid
(50 μM) and koetjapic acid (50 μM) demonstrated significant cytotoxi-
city against the cellular proliferation (Fig. 4B and C, respectively). In-
terestingly, KKA (50 μM) displayed poor cytotoxic effect against the
Fig. 6. Effect of KKA on migration of EA.hy926 cells.
A) In untreated group, the endothelial cells the migrated successfully which
resulted in complete closure of wound after 18 h, whereas in KKA treated group,
the wound remained open even after 18 h incubation. KKA (7 μM) caused sig-
nificant inhibition of endothelial cell migration. At a concentration of 14 μg/
mL, KKA caused severe dislodgement of monolayer of endothelial cells with
complete inhibition of migration of the cells.
B) Graphical representation of the time and dose-dependent inhibitory effect of
KKA on migration of EA.hy926 cells (values are presented in mean ± S.E.M,
P < 0.005, n = 6).
Fig. 7. Effect of KKA in tube formation assay. EA.hy926 (2× 104 cells/well)
were plated on Matrigel precoated 96-well plates and treated with different
concentrations of KKA for 24 h. Phase contrast micrographs showing the effects
of KKA on differentiation of the cells.
A) Photomicrographic image represents negative control, shows the endothelial
cells grown on the 3-dimentional matrigel media differentiated into tube for-
mation. The picture clearly shows prominently thick-cell covered areas
(brackets), tubes (arrows), loops (Lo) and branching points (b).
B) Photomicrograph shows the effect of treatment of KKA (20 μM) caused
weakening of the bridges in tube-like structure (arrow head) and reduced
density of branching points (b) demonstrating moderate anti-angiogenic effect.
C) Treatment with KKA (30 μM) shows significant abrogation of the network
structure (arrow head) of the endothelial cells which is evident through the loss
of cell covered area (brackets), thinned tubes (arrow head), and feeble
branching points (b).
D) Treatment with koetjapic acid (30 μM) shows weakening of the network
structure (arrow head) of the endothelial cells with 68.92 ± 2.3 % inhibition.
E) Graphical depiction of dose-dependent inhibitory effect of KKA on the on the
height and width of capillary-tube like structures of HUVECs. Values are ex-
pressed as mean ± S.E.M, three independent experiments (n=3).* =
p < 0.05, ** = p < 0.01 and *** = p < 0.001. KA=koetjapic acid;
KKA=potassium koetjapate.
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endothelial cells as the population of the cells had not been affected by
the treatment (Fig. 4D). However, all the tested compounds caused
reduction in the percentage of EA.hy926 viable cells gradually in a dose
dependent manner compared to the vehicle treated group (Fig. 4E). The
IC50 values of KA and KKA towards EA.hy926 cells were calculated to
be 71.2 μM and 142 μM, respectively.
3.3.2. KKA suppresses sprouting of blood vessels from rat aorta
The inhibitory effect of KKA on blood vessel outgrowth from the rat
aortic explants is displayed in Fig. 5. The negative control group, which
shows the prominent sprouting of microvessels from the aortic ring is
presented in Fig. 5A. KKA caused significant loss of the extent of length
and number of the microvessels in the isolated aortic explants (Fig. 5B
to E). The anti-neovascularization effect of KKA can be compared with
that of the positive control, betulinic acid (100 μM) which caused sig-
nificant inhibition in formation of blood vessels in aortic rings (Fig. 5F).
The graphical presentation of comparative and dose-dependent analysis
of sprouting of blood vessels in negative control (0.1 % DMSO), positive
control group (betulinic acid) and KKA treated groups (Fig. 5G). Ac-
cording to percentage decrease in blood vessel outgrowth treated with
different doses of KKA, the IC50 of KKA is estimated as 18.4 ± 4.2 μM.
3.3.3. KKA inhibits migration of endothelial cells
Inhibitory effect of KKA on the motility and migration of EA.hy926
cells is displayed in Fig. 6. A scratch was created in the monolayer of
EA.hy926 cells. The wound (scratch) of untreated cells was closed
completely within 18 h (Fig. 6A). Whereas, the treatment groups show
incomplete wound closure even after 18 h of incubation, as KKA
treatment caused significant (p < 0.05) inhibition of cellular migra-
tion. Wound closure percentages after 12 h were calculated to be 33.41
% and 30.23 % at 7 and 14 μM of KKA, respectively. Whereas, the
wound closure was reached to be 62.43 % and 51.3 % after 18 h of
treatment with 7 and 14 μM of KKA, respectively. The significant in-
hibition of migration of EA.hy926 cells by KKA can be observed in the
graphical presentation (Fig. 6B) which depicts the reduced percentage
migration of the cells across the artificially created wound in compar-
ison with negative control group (Fig. 6B).
3.3.4. KKA inhibits differentiation of endothelial cells on Matrigel Matrix
Treatment of EA.hy926 cells with KA inhibited the growth factor
induced differentiation in a dose-dependent manner. Because of the
growth factor influenced differentiation, a well prominent tube-like
network was formed in the endothelial cells (Fig. 7A). Whereas, treat-
ment with KKA at 20 μM concentrations (Fig. 7B), affected the tube-like
structure and decreased the length and width of the network through
which the endothelial cells connected and established the vasculature
like structure. At 30 μM, KKA completely abrogated endothelial tube
formation (Fig. 7C). Koetjapic acid (KA) which was used as reference
(Fig. 7D) in this study showed less activity (68.92 ± 2.3 % at 30 μM) as
compared to the equivalent dose of KKA (p < 0.05). The dose depen-
dent effects of KKA on width and length of endothelial cell tube-net-
work is depicted in Fig. 7E which shows significant inhibition of
EA.hy926 tube formation by KA and KKA as compared to negative
control (p < 0.05).
3.3.5. KKA blocks production of vascular endothelial growth factor (VEGF)
The concentration of VEGF in untreated and treated (KKA and
koetjapic acid) endothelial cells (EA.hy926) is depicted in Fig. 8. The
results show a significant decrease (p < 0.05) in the amount of VEGF
observed in koetjapic acid and KKA treated cells when compared with
untreated cells. Concentration of VEGF in the control group (distilled
water) was 89 ± 2.21 pg/mL. Whereas, concentrations of VEGF in cells
treated with 75 and 150 μM of KKA, and 75 and 150 μM of KA are
151.2 ± 3.9 (p < 0.001), 102.34 ± 3.4 (p < 0.001), 189.2 ± 4.3
(p < 0.05), and 184 ± 5.4 pg/mL (p < 0.001), respectively. When
comparison is made between treatment groups, KKA shows significantly
more potent (p < 0.05) anti-VEGF activity at higher concentration
(150 μm/mL) compared to koetjapic acid at higher concentration
(150 μm/mL) which indicates that KKA has better efficacy in inhibition
of VEGF activity compared to KA which is used as reference in this
study.
3.3.6. KKA inhibits matrigel induced vasculature in nude mice
Overall results of Matrigel plug assay illustrating the antiangiogenic
activity is depicted in Fig. 9. Matrigel was implanted in nude mice
subcutaneously and then allowed 21 days to observe the formation of
neovascularization. Mice bearing the Matrigel plug that represents ne-
gative control group (Fig. 9A). The Matrigel plug harvested from the
negative control group is depicted in Fig. 9B. The morphological studies
of the isolated Matrigel plug from the negative control group revealed
blood vessels formed most prominently, whereas KKA treatment caused
significant (*** = p < 0.001) reduction in the formation of new blood
vessels. The animal and the Matrigel plug corresponding to the KKA
treatment with 50, 100 and 200mg/kg body weight are represented in
Fig. 9C–D, E–F and G–H, respectively. Treatment with standard drug,
Imatinib (100mg/kg) has shown significant (*** = p < 0.01) anti-
neovascularization in the animals bearing Matrigel (Fig. 9I), as the
isolated Matrigel plug (Fig. 9J) showed reduced formation of blood
vessels. The Matrigel plug harvested from higher concentration of KKA
(200mg/kg)-treated animals revealed drastic reduction of blood vessels
in the Matrigel implant. The findings were also confirmed in the H&E
stained cross-sections of the excised Matrigel implants (Fig. 10). Mi-
crotome section of the Matrigel from the negative control group
(Fig. 10A) displays high vascularization (circles) and more proliferation
of HCT-116 cells compared to the other KKA treated groups (Fig. 10B
and C). The anti-neovascularization effect of KKA is comparable with
that of the standard reference, imatinib tested at 100mg/kg (Fig. 10D).
The average volume of Matrigel plug harvested from the re-
presentative animals is shown in Fig. 10E. The plugs excised from the
negative control group demonstrated larger size volume of 633.9 ± 23
cm3. Whereas, KKA showed a dose-dependent effect on the plug volume
with 304.0 ± 16 cm3, 220.5 ± 39 cm3, and 200.7 ± 11 cm3 for the
doses 50, 100 and 200mg/kg, respectively. The effect of KKA was
comparable with the positive control Imatinib (100mg/kg) which ex-
hibited 232.8 ± 11 cm3 plug volume. The average blood vessel counts
taken from 10 microscopic fields (low magnification power) in Matrigel
sections from representative groups are displayed in a graphical re-
presentation in Fig. 10F. The graph shows that the average blood vessel
count in the negative control group was 109 ± 5, whereas treatment
with KKA has significantly (P < 0.01) inhibited formation of new
blood vessels in the Matrigel implants, as the total mean counts of blood
vessels were 46 ± 3 and 19 ± 2 and 11 ± 5 at concentrations of 50,
Fig. 8. Effect of KKA on the release of VEGF-A from EA.hy926 cells. Significant
decrease in the secretion of VEGF was detected in all the treatment groups.
Values shown are mean ± SD of three independent experiments (n= 3). ns =
* = p < 0.05, ** = p < 0.001 and *** = p < 0.001, respectively.
S.F. Jafari, et al. Biomedicine & Pharmacotherapy 130 (2020) 110602
8
100 and 200mg/kg, respectively. The blood vessel count in Matrigel
implants from the mice treated with imatinib at 100mg/kg was cal-
culated to be 20 ± 4.
In the present study, antiangiogenic potentials of KKA were
investigated with a series of in vitro and in vivo assays. Results of rat
aortic ring assay revealed a strong inhibitory effect of KKA on neo-
vascularization in aortic explants. In order to examine whether the
observed effect on rat aortic ring assay was because of inhibition of
Fig. 9. In vivo anti-angiogenic effects of KKA was determined using
Matrigel plug model in athymic nude mice. KKA exhibited strong in-
hibitory effect on vascularization in Matrigel plugs implanted in nude
mice when compared to negative control treated group.
A) Animals represent negative control group.
B) Matrigel plug isolated from the negative control group.
C) Animals treated with KKA (50mg/kg).
D) Matrigel plug isolated from KKA (50mg/kg) treated group.
E) Animals treated with KKA (100mg/kg).
F) Matrigel plug isolated from KKA (100mg/kg) treated group.
G) Animals treated with KKA (200mg/kg).
H) Matrigel plug isolated from KKA (200mg/kg) treated group.
I) Animals treated with imatinib (100mg/kg).
J) Matrigel plug isolated from imatinib (100mg/kg) treated group.
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endothelial cells proliferation or not, the MTT assay was conducted on
EA.hy926 cells. KKA displayed a very poor cytotoxic effect on the
human endothelial cells with a high IC50 value (142 μM) which de-
monstrates that KA is not a cytotoxic compound against EA.hy926 cells.
Interestingly, KKA has shown reduced cytotoxicity on EA.hy926 cells
compared to the parent molecule koetjapic acid which has shown sig-
nificant cytotoxic effect with IC50 71.2 μM. Consequently, the results of
rat aortic ring assay and the MTT assay on EA.hy926 cell imply that the
anti-angiogenic effect presented by KKA is not because of the cytotoxic
essence of the compound, but may be more related to inhibition of
endothelial functions such as motility, migration, differentiation and/or
inhibition of VEGF signaling. To find out the mechanism of anti-
angiogenesis of KKA, its effect was examined on several major steps of
angiogenesis, such as migration, differentiation and VEGF expression in
human endothelial cells. In addition, the effect of KKA was also studied
on formation of Matrigel-induced vasculature in nude mice. The results
show that KA significantly suppressed all the mentioned steps. The
critical cascade of angiogenesis is the degeneration of extracellular
matrix and vascular basement membrane which paves the way for en-
dothelial cells to migrate into the perivascular space in the direction of
angiogenic stimuli, mostly VEGF. Endothelial cells follow chiefly the
chemotaxic migration towards the chemoattractants such as VEGF [18].
In the present study, KKA displays significant improvement in inhibi-
tion of VEGF activity compared to KA, which was used as reference in
this study. The findings of the present study indicate a significant en-
hancement in antiangiogenic efficacy of KKA in comparison with its
parent compound koetjapic acid. KKA has shown antiangiogenic
properties by stopping sprouting of rat aortic microvessels, and mi-
gration and differentiation of endothelial cells. In addition, KKA dis-
plays antiangiogenic activity by suppressing VEGF production. Previous
studies have shown that KA induces cytotoxicity via apoptotic pathway
by inhibiting the Wnt and HIF-1α genes activities [1]. In addition, KA
has also demonstrated remarkable antiangiogenic effects via VEGF in-
hibition [19]. Several studies have reported that Wnt and HIF-1α genes
have been strongly coupled with VEGF inhibition [20,21]. A growing
number of anticancer agents have been shown to inhibit VEGF pathway
via blocking hypoxia inducible factor (HIF) and Wnt genes activity [22].
Based on these facts, the mechanism of action for KA and KKA can be
established that involves suppression of HIF-1α and Wnt genes activity
which in turn blocks VEGF pathway and subsequently inhibits angio-
genesis. Findings of the present study showed that potassium koetjapate
(KKA) has shown improved cytotoxic as well as antiangiogenic effects
compared to koetjapic acid (KA). The improved efficacy of KKA can be
due to the improved solubility and bioavailability.
4. Conclusion
Based on the outcome of the current work, it can be concluded that
a simple and sensitive HPLC method has been successfully applied to
determine the pharmacokinetic characteristics of potassium koetjapate
(KKA) in rats. The results indicated that KKA was readily absorbed into
the rat blood upon oral administration. Furthermore, the anti-
angiogenic studies revealed remarkable improvement in the efficacy of
KKA compared to the parent compound, koetjapic acid. KKA suppressed
angiogenesis by inhibiting endothelial functions and VEGF expression.
The enhanced bioefficacy of KKA could probably be attributed to its
enhanced solubility and bioavailability. Further preclinical and clinical
studies are warranted to develop KKA as a promising therapeutic agent
against angiogenesis related disorders.
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Fig. 10. H&E stained cross-sections taken from Matrigel plugs implanted sub-
cutaneously in representative groups of animals.
A) Section from negative control group shows prompt and well-developed
blood vessels (indicated with circles).
B) Section from imatinib treated group (positive control) demonstrates less
blood vessels when compared to the negative control.
C) Sections from KKA (100mg/kg) treated group shows moderate inhibition of
blood vessel formation in Matrigel plugs.
D) Sections from KKA (200mg/kg) treated group shows pronounced inhibition
of blood vessel formation in Matrigel plugs.
E) Graphical representation of the effect of KKA on the volume of Matrigel plug.
(*** = p < 0.001, n= 6, values are mean ± SEM of 10 low power micro-
scopic fields). NC=negative control; KKA=potassium koetjapate. Imatinib is
used as positive control.
F) Graphical representation of the effect of KKA on the mean blood vessel count
(average of 10 microscopic fields) in Matrigel sections. (*** = p < 0.001,
n= 10, values are mean ± SEM of 10 low power microscopic fields).
NC=negative control; KKA=potassium koetjapate. Imatinib is used as posi-
tive control.
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